摘要:
Described here are devices and methods for treating one or more conditions or symptoms associated with a tonsil procedure. In some variations, a drug-releasing device may be at least partially delivered to one or more tonsillar tissues before, during, or after a tonsil procedure. In some variations, the drug-releasing device may be configured to be biodegradable. In other variations, the drug-releasing device may comprise one or more hemostatic materials or one or more adhesives. The drug-releasing device may be configured to release one or more drugs or agents, such as, for example, one or more analgesics, local anesthetics, vasoconstrictors, antibiotics, combinations thereof and the like.
摘要:
Described here are devices and methods for crimping self-expanding devices. The crimping devices may be useful for crimping a variety of different self-expanding devices (whether such devices are biodegradable or bio-durable). The crimping devices may have crimping members to engage the self-expanding device to reduce the device from an expanding configuration to an unexpanded configuration. The crimping member may comprise or include a suture, wire, ribbon, guiding hoop, pusher, prong, holding bar, balloon, jaws, combinations thereof, or the like. The crimping devices may also include or comprise a holding structure to hold the self-expanding device in an unexpanded or expanded configuration.
摘要:
Described here are devices and methods for crimping self-expanding devices. The crimping devices may be useful for crimping a variety of different self-expanding devices (whether such devices are biodegradable or bio-durable). The crimping devices may have crimping members to engage the self-expanding device to reduce the device from an expanding configuration to an unexpanded configuration. The crimping member may comprise or include a suture, wire, ribbon, guiding hoop, pusher, prong, holding bar, balloon, jaws, combinations thereof, or the like. The crimping devices may also include or comprise a holding structure to hold the self-expanding device in an unexpanded or expanded configuration.
摘要:
Pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating heart failure diseases such heart failure with preserved ejection fraction (HFPEF) alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
摘要:
Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.
摘要:
Pharmaceutical compositions comprising Fatty Acid Fumarate Derivatives, and methods of using Fatty Acid Fumarate Derivatives and pharmaceutical compositions thereof for treating heart failure diseases, including heart failure with preserved ejection fraction (HFPEF), comprising the administration of an effective amount of a Fatty Acid Fumarate Derivative alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
摘要:
Pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating heart failure diseases such heart failure with preserved ejection fraction (HFPEF) alone or in combination with statins (HMG-CoA reductase inhibitors) are disclosed.
摘要:
Pharmaceutical preparations and methods for treating or preventing a heart failure disease, including heart failure with preserved ejection fraction (HFPEF), with one or more dialkyl fumarates alone or in combination with one or more second agents are provided herein. In some embodiments, the pharmaceutical preparations are in the form of micro-tablets or pellets.
摘要:
Described herein are pharmaceutical compositions for the treatment of sexual dysfunction in an individual. In some embodiments, the pharmaceutical composition includes a prolactin variant having a glycine residue at position 129 substituted with an amino acid other than glycine. In one embodiment, the amino acid is arginine. In one embodiment, the prolactin variant further comprises an N-terminal deletion. In one embodiment, the prolactin variant is conjugated to a H(OCH2CH2)nOH molecule (e.g., n equals any number from 1 to 6). In some embodiments, the pharmaceutical composition is delivered to the individual by a microneedle patch or an inhalable formulation.
摘要:
Methods and pharmaceutical compositions comprising one or more prodrugs (e.g., aminoalkyl prodrugs) of monomethyl fumarate (MMF) thereof are provided herein for the treatment of a heart failure disease, including heart failure with preserved ejection fraction. The compounds of the present disclosure are configured to be converted in vivo, upon oral administration, to monomethyl fumarate. Upon conversion, the active moiety (i.e., monomethyl fumarate) of various embodiments is effective in treating subjects suffering from a heart failure disease, including heart failure with preserved ejection fraction.